Printer Friendly

CELLEGY BOLSTERS PRODUCT DEVELOPMENT CAPABILITIES: APPOINTS VICE PRESIDENT, RESEARCH AND DEVELOPMENT, AND DIRECTOR OF CLINICAL TRIALS

 NOVATO, Calif., Aug. 19 /PRNewswire/ -- Cellegy Pharmaceuticals Inc. today announced the appointments of Daniel Morgan Ford, Ph.D., 51, to the position of vice president, Research and Development, and Cynthia Selfridge, 48, as director, Clinical Trials.
 In the newly created post of vice president, Research and Development, Ford will be responsible for overseeing the company's topical drug development program, as well as directing Cellegy's efforts to identify new product candidates. He will report to Jerry Simmons, Cellegy's president and chief executive officer. As director of clinical trials, Selfridge, who joins Cellegy from Xoma Corp., will direct the clinical development of Cellegy's dermatological product candidates. Selfridge will report to Mary Levins, vice president, Regulatory and Quality Control.
 "These individuals bring tremendous expertise in pharmaceutical and clinical development to Cellegy," said Simmons. "We are moving forward rapidly as our lead product candidate, Glylorin(TM) moves toward its Phase III clinical testing for congenital ichthyosis. In addition, four new product candidates are moving to the clinic as anticipated."
 Ford most recently served as president of Cubicon Inc., a consulting company specializing in cutaneous biology. He advised major pharmaceutical and cosmetic companies in the areas of skin care product development, product safety and efficacy, regulatory affairs and technical problem solving.
 Ford began his career as a scientist with Syntex Research and was awarded an NIH pre-doctoral fellowship for basic research related to the skin with Dr. William Montagna at the Oregon Primate Center.
 Selfridge brings to Cellegy 12 years of experience in clinical research. In addition to Xoma, where she worked as manager of clinical research, Selfridge held clinical positions at Cholestech Inc. and Genentech.
 Cellegy embraces a unique scientific approach to treating skin diseases based on its understanding that the stratum corneum (or top layer of skin) is active metabolically and possesses the ability to stimulate the release of biological response modifiers. Cellegy believes it is the first company to focus on the role the epidermis plays in regulating processes that create the disease.
 Cellegy Pharmaceuticals Inc. is a privately held biopharmaceutical company developing novel dermatological products to treat and prevent skin disorders and chronic skin diseases, minimize the effects of aging and deliver drugs.
 -0- 8/19/93
 /CONTACT: Gerald Simmons, president and CEO of Cellegy, 415-382-6770; or Kimberly Kraemer of Pondel Parsons & Wilkinson, 310-207-9300, for Cellegy/


CO: Cellegy Pharmaceuticals Inc. ST: California IN: MTC SU: PER

LM-JL -- LA009 -- 4268 08/19/93 11:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1993
Words:404
Previous Article:FLORIDA PROGRESS DECLARES QUARTERLY DIVIDEND OF 48 1/2 CENTS PER SHARE
Next Article:NATIONAL COMPUTER SYSTEMS REPORTS SECOND QUARTER RESULTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters